SEARCH

SEARCH BY CITATION

References

  • 1
    Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
  • 2
    Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N Engl J Med. 2002;346:257-270.
  • 3
    Stovner L, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193-210.
  • 4
    Lipton RB, Stewart WF. Migraine headaches: Epidemiology and comorbidity. Clin Neurosci. 1998;5:2-9.
  • 5
    Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics. 1998;13:667-676.
  • 6
    Hopkins A. The epidemiology of headache and migraine, and its meaning for neurological services. Schweiz Med Wochenschr. 1996;126:128-135.
  • 7
    Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
  • 8
    Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc. 1996;71:1055-1066.
  • 9
    Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract. 1996;42:36-42.
  • 10
    Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: A managed care perspective. Arch Intern Med. 1999;159:857-863.
  • 11
    Chang M, Rapoport AM. Acute treatment of migraine headache. Tech Reg Anesth Pain Manag. 2009;13:9-15.
  • 12
    Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13(Suppl 2):S31-S70.
  • 13
    Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007;13:39-44.
  • 14
    Tfelt-Hansen P, Vries PD, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259-1287.
  • 15
    Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: A double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia. 2006;26:871-874.
  • 16
    Lavonas EJ, Ford MD. Antipsychotics. In: Marx JA , Hockberger RS , Walls RM , eds. Rosen's Emergency Medicine: Concepts and Clinical Practice, 5th edn. St. Louis, MO: C.V. Mosby; 2002:2174-2175.
  • 17
    Peroutka SJ, Jones WT. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Neurology. 1997;49:201-206.
  • 18
    Ghelardini C, Galeotti N, Uslenghi C, Grazioli I, Bartolini A. Prochlorperazine induces central antinociception mediated by the muscarinic system. Pharmacol Res. 2004;50:351-358.
  • 19
    Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics. 2012;129:1411-1420.
  • 20
    Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007;297:1443-1454.
  • 21
    Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: Guideline for good clinical practice. J Postgrad Med. 2001;47:45-50.
  • 22
    World Medical Association. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects (Seoul, South Korea, 2008) Available at: http://www.wma.net/en/30publications/10policies/b3/.
  • 23
    Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl. 1):9-160.
  • 24
    Silberstein SD, Saper JR, Freitag F. Migraine: Diagnosis and treatment. In: Silberstein SD , Lipton RB , Dalessio DJ , eds. Wolff's Headache and Other Head Pain, 7th edn. New York, NY: Oxford University Press; 2001:121-237.
  • 25
    Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial. Headache. 2006;45:973-982.
  • 26
    Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998;55:210-217.
  • 27
    Diener HC, Peil H, Aicher B. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: A post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2011;31:1466-1476.
  • 28
    Tfelt-Hansen P, Bousser MG, Solomon S, et al. Guidelines for controlled trials of drugs in migraine. In: International Headache Society Members' Handbook. Oslo, Norway: Scandinavian University Press; 1998-1999:111-133.
  • 29
    Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: Results of a multicenter, randomized, placebo-controlled study. Clin Ther. 2004;26:214-223.
  • 30
    Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial. Headache. 2005;45:973-982.
  • 31
    Tfelt-Hansen P, Bach FW, Daugaard D, Tsiropoulos I, Riddersholm B. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: A randomised, double-blind, placebo-controlled study. J Headache Pain. 2006;7:389-394.
  • 32
    Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S. Eletriptan steering committee. Eletriptan vs Sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study. Neurology. 2002;59:1210-1217.
  • 33
    Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol. 2001;58:944-950.
  • 34
    Habib AS, Reuveni J, Taguchi A, White WD, Gan TJ. A comparison of ondansetron with promethazine for treating postoperative nausea and vomiting in patients who received prophylaxis with ondansetron: A retrospective database analysis. Anesth Analg. 2007;104:548-551.
  • 35
    Lewis KS. Pediatric headache. Semin Pediatr Neurol. 2010;17:224-229.
  • 36
    Skidgel RA, Kaplan A, Erdos E. Histamine, bradykinin, and their antagonists. In: Brunton L , Chabner B , Knollman B , eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 12th edn. Columbus, OH: McGraw-Hill; 2011:920-924.
  • 37
    Hasler G, Buysse DJ, Gamma A, et al. Excessive daytime sleepiness in young adults: A 20-year prospective community study. J Clin Psychiatry. 2005;66:521-529.
  • 38
    Hardman JG , Limbird LE , eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th edn. New York, NY: McGraw-Hill; 1996.
  • 39
    Palazzo MGA, Strunin L. Anaesthesia and emesis: II. Prevention and management. Can Anaesth Soc J. 1984;31:407-415.
  • 40
    Peroutka SJ, Snyder SH. Antiemetics: Neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982;1:658-659.
  • 41
    Bain WA, Broadbent JL, Warin RP. Comparison of anthisan (mepyramine maleate) and phenergan as histamine antagonists. Lancet. 1949;2:47-52.
  • 42
    Tarkkila P, Törn K, Tuominen M, Lindgren L. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Acta Anaesthesiol Scand. 1995;39:983-986.
  • 43
    Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache. 1995;35:256-259.
  • 44
    Buzdar AU, Esparza L, Natale R, et al. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. Am J Clin Oncol. 1994;17:417-421.
  • 45
    Lackner JR, Graybiel A. Use of promethazine to hasten adaptation to provocative motion. J Clin Pharmacol. 1994;34:644-648.
  • 46
    Terndrup TE, Dire DJ, Madden CM, Davis H, Cantor RM, Gavula DP. A prospective analysis of intramuscular meperidine, promethazine, and chlorpromazine in pediatric emergency department patients. Ann Emerg Med. 1991;20:31-35.
  • 47
    Malamed SF. Sedation: A Guide to Patient Management, 5th edn. California: C. V. Mosby Co., Elsevier; 2010:95-110.
  • 48
    Braude D, Soliz T, Crandall C, Hendey G, Andrews J, Weichenthal L. Antiemetics in the ED: A randomized controlled trial comparing 3 common agents. Am J Emerg Med. 2006;24:177-182.
  • 49
    Braude D, Crandall C. Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: A randomized, double-blind, noninferiority trial. Acad Emerg Med. 2008;15:209-215.
  • 50
    Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache. 1998;38:737-747.
  • 51
    Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21:173-175.
  • 52
    Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache. 1998;38:184-190.
  • 53
    Spierings ELH. Optimum-dose determination of the triptans. Headache. 2000;40:433-434.
  • 54
    Lipton RB, Stewart WF, Cady RK, et al. Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study. Headache. 2000;40:783-791.
  • 55
    Faiqa Q, Donald L. Managing headache in the pediatric emergency department. Clin Pediatr Emerg Med. 2003;4:159-170.
  • 56
    Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol. 2008;23:3-14.
  • 57
    Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand. 2005;111:171-176.
  • 58
    Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol. 2002;54:188-202.
  • 59
    Peterlin BL, Calhoun AH, Siegel S, Mathew NT. Rational combination therapy in refractory migraine. Headache. 2008;48:805-819.